HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $3 price target.

February 12, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Sangamo Therapeutics with a $3 price target.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on Sangamo Therapeutics' stock price. Analyst ratings, especially those that are positive, can influence investor sentiment and stock performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100